To confirm the antimetastatic potential of BHMPS, a new synthetic compound that can inhibit Rab27a expression [14], we first verified Rab27a expression in breast cancer cell lines with different subtypes, including MDA-MB-231 and BT549 for TNBC, BT474 for luminal B, and MCF7 for luminal A molecular subtypes. Here, RAB27A is linked to breast carcinoma.